Mr. Chair, I thank our hon. colleague for his remarks. Like him, I have noticed that this problem is much more infrequent in Quebec and other jurisdictions that have a high quality, or at least strict, code of conduct. It is no coincidence that this industry has taken off in provinces with more, shall we say, flexible codes. The lack of such rules has created this situation.
So I want to ask my colleague if he too realizes that the problem boils down to the fact that the United States—how ironic—which invented consumer protection legislation, is apparently incapable of adopting legislation for consumers regarding pharmaceutical products. It adopted legislation on vehicle windshield height and all sorts of things. Recalls of defective vehicles and so forth originated in the United States.
However, for reasons beyond my comprehension, that same society is unable to adopt legislation protecting its consumers from, in the eyes of some, overly high prices or, at least, prices much higher than ours, and these people purchase their supply from a place that better protects its consumers, meaning from us. Therein lies the problem.
I fail to understand the reaction of some American legislators who say that importing drugs into their country is illegal. In truth, they want to avoid, at all costs, saying that they will enforce that legislation, because this could cost them votes back home.
So, I take issue with the comments of our colleague opposite, the member from Manitoba, who is saying that, since it is illegal to import drugs into the United States, bulk imports must be prohibited. Individual imports are illegal, but we have to ignore this. Only the provision on bulk imports, and not the other, must be enforced.
I want to hear what my colleague thinks about that.